Abvc Biopharma (ABVC) Net Income towards Common Stockholders (2010 - 2026)

Abvc Biopharma (ABVC) has 16 years of Net Income towards Common Stockholders data on file, last reported at -$1.3 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 241.4% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.8 million (down 186.5% YoY) and the FY2025 annual result came in at -$8.4 million, down 259.29% from the prior year.
• Net Income towards Common Stockholders grew to -$1.3 million in Q1 2026, from -$3.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $10.4 million in Q4 2024 to a low of -$6.0 million in Q1 2022.
• A 5-year average of -$874697.5 and a median of -$1.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 1215.93% — and 2025, when it slumped 1016.78%.
• Tracing ABVC's Net Income towards Common Stockholders over 5 years: stood at -$556480.0 in 2022, then soared by 1215.93% to $6.2 million in 2023, then soared by 67.33% to $10.4 million in 2024, then plunged by 129.03% to -$3.0 million in 2025, then soared by 55.74% to -$1.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.3 million (Q1 2026), -$3.0 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.